SPONSOR
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Total Trials
3
Recruiting
3
Phases
Phase 2, Phase 3, Phase 3
Conditions studied: Biphenotypic Acute LeukemiaAcute Lymphoblastic LeukemiaMyeloblastic LeukemiaBilinear LeukemiaMalignant Lymphoma, Non-HodgkinMyelodysplastic SyndromeAcute Myeloid Leukemia, RelapsedAcute Lymphoblastic Leukemia, High RiskAcute Myeloid Leukemia, High RiskAcute Lymphoblastic Leukemia, Relapse
Federal Research Institute of Pediatric Hematology, Oncology and Immunology is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Bilinear Leukemia.
The trial portfolio spans Phase 2, Phase 3, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Federal Research Institute of Pediatric Hematology, Oncology and Immunology
How many clinical trials has Federal Research Institute of Pediatric Hematology, Oncology and Immunology sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Federal Research Institute of Pediatric Hematology, Oncology and Immunology, of which 3 are actively recruiting participants. These trials cover conditions including Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, Myeloblastic Leukemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Federal Research Institute of Pediatric Hematology, Oncology and Immunology research focus on?
Federal Research Institute of Pediatric Hematology, Oncology and Immunology clinical trials span Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Bilinear Leukemia, Malignant Lymphoma, Non-Hodgkin, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Federal Research Institute of Pediatric Hematology, Oncology and Immunology clinical trial?
To participate in a Federal Research Institute of Pediatric Hematology, Oncology and Immunology trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Federal Research Institute of Pediatric Hematology, Oncology and Immunology trials with current recruitment status updated daily.
Clinical Trials by Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NCT06756152 Phase 2, Phase 3
Recruiting
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Biphenotypic Acute Leukemia
NCT07366801 Phase 2, Phase 3
Recruiting
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Acute Myeloid Leukemia, Relapsed
NCT06071897 Phase 3
Recruiting
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
Neuroblastoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology